Short- and long-term safety of glaucoma drugs

Joel S. Schuman

    Research output: Contribution to journalReview articlepeer-review


    Glaucoma, a leading cause of blindness worldwide, is a chronic neurodegenerative disorder. Patients with glaucoma may require long-term administration of intraocular pressure (IOP)-lowering medications. These medications belong to several classes of molecules including β-adrenergic blockers, cholinergic agents, α -adrenergic agonists, carbonic anhydrase inhibitors and ocular hypotensive lipids. Most adverse effects associated with IOP-lowering medications are mild and ocular in nature; however, several of them are associated with systemic risks as well as serious ocular effects, especially following chronic use. The following review discusses the acute and long-term effects of commonly used IOP-lowering medications.

    Original languageEnglish (US)
    Pages (from-to)181-194
    Number of pages14
    JournalExpert Opinion on Drug Safety
    Issue number2
    StatePublished - Jul 1 2002


    • carbonic anhydrase inhibitors
    • cholinergic agents
    • glaucoma
    • long-term safety
    • ocular hypotensive lipids
    • α-adrenergic agonists
    • β-adrenergic blockers

    ASJC Scopus subject areas

    • Pharmacology (medical)


    Dive into the research topics of 'Short- and long-term safety of glaucoma drugs'. Together they form a unique fingerprint.

    Cite this